ICS Medical Advisory (ICSMA-20-233-01)

Philips SureSigns VS4

Legal Notice

All information products included in https://us-cert.gov/ics are provided "as is" for informational purposes only. The Department of Homeland Security (DHS) does not provide any warranties of any kind regarding any information contained within. DHS does not endorse any commercial product or service, referenced in this product or otherwise. Further dissemination of this product is governed by the Traffic Light Protocol (TLP) marking in the header. For more information about TLP, see https://www.us-cert.gov/tlp/.


 

1. EXECUTIVE SUMMARY

  • CVSS v3 6.3
  • ATTENTION: Exploitable remotely
  • Vendor: Philips
  • Equipment: SureSigns VS4
  • Vulnerabilities: Improper Input Validation, Improper Access Control, Improper Authentication

2. RISK EVALUATION

Successful exploitation of these vulnerabilities could allow an attacker access to administrative controls and system configurations, which could allow changes to system configuration items causing patient data to be sent to a remote destination.

3. TECHNICAL DETAILS

3.1 AFFECTED PRODUCTS

The following versions of SureSigns VS4, a vital signs patient monitor, are affected:

  • SureSigns VS4 A.07.107 and prior

3.2 VULNERABILITY OVERVIEW

3.2.1    IMPROPER INPUT VALIDATION CWE-20
The product receives input or data, but it does not validate or incorrectly validates that the input has the properties required to process the data safely and correctly.
CVE-2020-16237 has been assigned to this vulnerability. A CVSS v3 base score of 2.1 has been calculated; the CVSS vector string is (AV:P/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:L).

3.2.2    IMPROPER ACCESS CONTROL CWE-284
The software does not restrict or incorrectly restricts access to a resource from an unauthorized actor.
CVE-2020-16241 has been assigned to this vulnerability. A CVSS v3 base score of 6.3 has been calculated; the CVSS vector string is (AV:P/AC:H/PR:N/UI:N/S:C/C:L/I:L/A:H).

3.2.3    IMPROPER AUTHENTICATION CWE-287
When an actor claims to have a given identity, the software does not prove or insufficiently proves the claim is correct.
CVE-2020-16239 has been assigned to this vulnerability. A CVSS v3 base score of 4.9 has been calculated; the CVSS vector string is (AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:N/A:N).

3.3 BACKGROUND

  • CRITICAL INFRASTRUCTURE SECTORS: Healthcare and Public Health
  • COUNTRIES/AREAS DEPLOYED: Worldwide
  • COMPANY HEADQUARTERS LOCATION: Netherlands

3.4 RESEARCHER

Cleveland Clinic reported these vulnerabilities to Philips.

4. MITIGATIONS

As a mitigation to these vulnerabilities, Philips recommends users change all system passwords on the SureSigns VS4 with unique passwords for each device and secure the device when not in use to prevent unauthorized access, as referenced in the Installation and Configuration Guide available on Incenter. Philips also recommends users consider replacing the SureSigns VS4 device with a newer technology.

Users with questions regarding specific SureSigns VS4 patient monitor installations and upgrade options should contact Philips service support or regional service support or call 1-800-722-9377.

Please see the Philips advisory for vulnerabilities discussed in this disclosure, and visit the Philips product security website for the latest security information for Philips products.

CISA recommends users take defensive measures to minimize the risk of exploitation of these vulnerabilities. Specifically, users should:

  • Implement physical security measures to limit or control access to critical systems.
  • Restrict system access to authorized personnel only and follow a least privilege approach.
  • Apply defense-in-depth strategies.
  • Disable unnecessary accounts and services.
  • Where additional information is needed, refer to existing cybersecurity in medical device guidance issued by the FDA.

CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.

CISA also provides a section for control systems security recommended practices on the ICS webpage on us-cert.gov. Several recommended practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.

Additional mitigation guidance and recommended practices are publicly available on the ICS webpage on us-cert.gov in the Technical Information Paper, ICS-TIP-12-146-01B--Targeted Cyber Intrusion Detection and Mitigation Strategies.

Organizations observing any suspected malicious activity should follow their established internal procedures and report their findings to CISA for tracking and correlation against other incidents.

No known public exploits specifically target these vulnerabilities. Low skill level is needed to exploit.


Contact Information

For any questions related to this report, please contact the CISA at:

Email: CISAservicedesk@cisa.dhs.gov
Toll Free: 1-888-282-0870

For industrial control systems cybersecurity information:  https://www.us-cert.gov/ics 
or incident reporting:  https://www.us-cert.gov/report

CISA continuously strives to improve its products and services. You can help by choosing one of the links below to provide feedback about this product.

This product is provided subject to this Notification and this Privacy & Use policy.

Was this document helpful?  Yes  |  Somewhat  |  No